Home > Healthcare > Medical Devices > Therapeutic Devices > Outpatient Oncology Infusion Market

Outpatient Oncology Infusion Market Share

Report ID: GMI5268
Published Date: Sep 2024
Report Format: PDF

Download Free Sample

Outpatient Oncology Infusion Market Share

The market is characterized by the presence of several key players and a focus on technological innovation and strategic partnerships. These companies invest significantly in research and development to introduce advanced and intelligent infusion pumps and associated devices. Strategic initiatives such as mergers, acquisitions, and collaborations are common strategies employed by key players to strengthen their market position and expand their geographic footprint. Emerging players also play a crucial role in the market by introducing innovative solutions aimed at improving procedural outcomes and patient care in outpatient oncology infusion.

Outpatient Oncology Infusion Market Companies

Prominent players operating in the outpatient oncology infusion industry include:

B. Braun Melsungen AG
Baxter
Becton, Dickinson, and Company
Fresenius Kabi
ICU Medical, Inc
IRadimed Corporation
Medtronic PLC
Micrel Medical Devices SA
Moog, Inc.
Nipro Corporation
Roche Diagnostics
Smiths Medical
Teleflex, Inc.
Terumo Corporation

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The outpatient oncology infusion industry was valued at USD 2.4 billion in 2023 and is anticipated to register a 10.6% CAGR from 2024 to 2032, driven by technological advancements in infusion pumps, the increasing prevalence of cancer, and the expansion of healthcare policies and insurance coverage.

The infusion pumps segment of outpatient oncology infusion market generated a revenue of USD 1.2 billion in 2023, due to their precision in drug delivery, ability to administer complex chemotherapy regimens, and improved patient outcomes.

North America outpatient oncology infusion industry was worth USD 1 billion in 2023 and will showcase a 10% CAGR through 2032, stimulated by the rising prevalence of cancer.

Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, and Moog, Inc., among others.